The effects of silodosin in the treatment of ureteral stent related symptoms
- 101 Downloads
The aim of the present study was to evaluate the outcome of silodosin in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents. We reviewed the data of 89 male patients with ureteral stones who had undergone placement of a double-J ureteral stent after retrograde ureteroscopy at Pusan National University Hospital in South Korea from June 2011 to May 2013. The patients enrolled in the study were sorted into two groups. Forty-six patients who were given silodosin (8 mg) once daily were sorted as group A, and forty-three patients who received no α1-blocker were sorted as group B (control group). All patients completed international prostate symptoms score/quality of life component of IPSS (IPSS/QoL) and visual analogue pain scale (VAPS) questionnaires 6 weeks after the stent placement. The mean age of all the patients was 57.9 ± 12.8 years (range, 27–84 years). There was a significant difference in the IPSS—total score (p = 0.029), storage subscore (p = 0.035) and voiding subscore (p = 0.017)—and QoL scores (p = 0.041), but no significant differences in the VAPS (p = 0.210). The present study showed that silodosin improved stent-related urinary symptoms and QoL without causing any serious side effects. Further clinical research in this area is warranted to better define the role of silodosin in current clinical practice.
KeywordsSilodosin Ureteral stent Symptom
This work was supported by a clinical research grant from Pusan National University Hospital in 2014.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Zimskind, P.D., Fetter, T.R., Wilkerson, J.L.: Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J. Urol. 97, 840–844 (1967)Google Scholar
- 6.Joshi, H.B., Okeke, A., Newns, N., et al.: Prevalence of urinary symptoms in patients with ureteric stents and its assessment using I-PSS and ICS questionnaires. Eur. Urol. 37, 125 (2000)Google Scholar
- 27.Shibata, K., Foglar, R., Horie, K., et al.: KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol. Pharmacol. 48, 250–258 (1995)Google Scholar